Shilpa Biocare takes 30.4% stake in Gate2Brain for brain cancer therapy
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shilpa Biocare, a wholly owned subsidiary of Shilpa Medicare, is taking a 30.4% strategic equity stake in Barcelona-based biotech Gate2Brain for Euro 7 million. Gate2Brain's lead candidate G2B-002 targets brain cancers like DIPG and pediatric glioblastoma, and holds Orphan Drug Designation from the US FDA and EMA. Shilpa will also act as the CMC, manufacturing, and regulatory partner. First-in-human trials are expected by FY28. This marks Shilpa's fourth such strategic partnership.
Strategic minority investment in a pre-clinical CNS delivery platform. Long-term value play, no near-term revenue impact. Pipeline diversification beyond core pharma.